← Back to Clinical Trials
Recruiting NCT05107947

NCT05107947 Light in Frail Elderly - the Effect of a Dynamic Light for Sleep and Circadian Rhythm

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05107947
Status Recruiting
Phase
Sponsor Region Skane
Condition Aged
Study Type INTERVENTIONAL
Enrollment 300 participants
Start Date 2022-10-31
Primary Completion 2028-03

Eligibility & Interventions

Sex All sexes
Min Age 65 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Biocentric light

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 300 participants in total. It began in 2022-10-31 with a primary completion date of 2028-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this project is to evaluate the effect of a dynamic light in order to improve the circadian rhythm, provide a better sleep and well-being, and in the long run an improved recovery. The primary question is whether dynamic artificial light with circadian stimulus can affect the circadian rhythm. The secondary question is whether this also provides better sleep and well-being. The group that is particularly interesting to study is a geriatric population that is more sensitive to circadian rhythm disorders, sleep disorders and confusion in connection with hospitalization and that can be of particular benefit from this intervention.

Eligibility Criteria

Inclusion Criteria: * Over the age of 65 years * Admitted to one of the included study rooms Exclusion Criteria: * Overdose addictive substance * Acute neurological disease * Melatonin treatment * Probable survival \<5 days * Severe visual impairment that makes reading impossible * Age \<65 years * Inability to understand Swedish in speech and writing * Inability to consent to participate in the study * The patient is on any of the following medicines: * Medications for Parkinson's disease * Neuroleptics (including lithium) * Dementia

Contact & Investigator

Central Contact

Madeleine Selvander, MD, PhD

✉ madeleine.selvander@med.lu.se

📞 +4640 33 32 27

Principal Investigator

Madeleine Selvander, MD, PhD

PRINCIPAL INVESTIGATOR

Lunds Universitet

Frequently Asked Questions

Who can join the NCT05107947 clinical trial?

This trial is open to participants of all sexes, aged 65 Years or older, studying Aged. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05107947 currently recruiting?

Yes, NCT05107947 is actively recruiting participants. Contact the research team at madeleine.selvander@med.lu.se for enrollment information.

Where is the NCT05107947 trial being conducted?

This trial is being conducted at Malmö, Sweden.

Who is sponsoring the NCT05107947 clinical trial?

NCT05107947 is sponsored by Region Skane. The principal investigator is Madeleine Selvander, MD, PhD at Lunds Universitet. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology